Efficacy and Safety of Lumiracoxib

Novartis

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis

Treatments: Drug: Lumiracoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00267215

CCOX189A2301

Details and patient eligibility

About

This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• Osteoarthritis of the knee
• Pain intensity at baseline of at least 50mm on a 100mm visual analog scale

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind